Tech-Enhanced Wellness Finds That Help You Recharge on YourUpdateTV
Lifestyle expert Meaghan Murphy partners with D S Simon Media and RENPHO to spotlight self-care tools designed to relieve screen fatigue and promote rest — all on sale now.
NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- As Prime Day deals hit full swing, RENPHO's best-selling eye massagers are gaining buzz for their smart design, built-in relaxation features, and relief from digital fatigue.
Featured products:
RENPHO Eyeris 1 Eye Massager
Perfect for winding down at the end of a long day, the Eyeris 1 delivers a calming blend of air compression, gentle heat, and Bluetooth-enabled music playback to help users release tension around the eyes and temples.
It targets 10 acupressure points around the orbital area and is particularly helpful for dry eyes, puffiness, or digital strain from prolonged screen exposure. With multiple massage modes and a soft clamshell design, it's both highly effective and travel-friendly
RENPHO Eyeris 3 Eye Massager:
For those looking for a premium experience, the Eyeris 3 builds on the foundation of the Eyeris 1 with voice control, a cooling gel mask, and a wider fit that supports better comfort across the face and nose bridge. Users can activate massage modes hands-free by saying, 'Hi Eyeris,' and select from multiple temperature and pressure levels — from light temple compression to full acupressure-based therapy.
Ideal for puffy eyes, headaches, or trouble sleeping, it's the ultimate upgrade for screen-tired eyes, with a portable build and travel bag included.
Meaghan calls these 'like a spa moment for your face,' and also reminds viewers that other RENPHO best-sellers — like the Mini Thermal Massage Gun, Smart Tape Measure, and 2025 Foot Massager — are all on sale now for Prime Day as well.
All featured items are available on Amazon with special Prime Day pricing from July 8th through July 11th.
About Meaghan Murphy
Meaghan Murphy is the author of Your Fully Charged Life, former editor-in-chief of Woman's Day, and a frequent guest on national programs like TODAY and Good Morning America. Her signature blend of upbeat advice and practical know-how makes her a go-to source for all things lifestyle.
About D S Simon Media:
The firm is well known as a leader in the satellite media tour industry and produces tours from its studio and multiple control rooms at its New York headquarters. Clients include top brands in healthcare, technology, travel, financial services, consumer goods, entertainment, retail and non-profits. Established in 1986 the firm has won more than 100 industry awards.
About YourUpdateTV: YourUpdateTV is a property of D S Simon Media. The video included and release was part of a media tour that was produced by D S Simon Media on behalf of RENPHO.
Dante Muccigrosso
Director of Media Integration & Client Reporting
E: [email protected]
C: 973.524.0104
A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/539636ef-2383-4c4c-8271-5d0fe76599dd
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
3 minutes ago
- Fox News
Doctor touts states for banning junk food from SNAP benefits amid push for healthier alternatives
Dr. Devi E. Nampiaparampil joins 'Fox & Friends' to discuss the impact of the junk food ban as the MAHA movement pushes healthier options and her take on the toxic impacts of plastic pollution.
Yahoo
31 minutes ago
- Yahoo
3 Healthcare Stocks Paying the Highest Dividends of 2025
Key Points SIGA Technologies has a sky-high dividend yield that comes with a catch. Pfizer's dividend remains strong despite a looming patent cliff. Spok Holdings offers an attractive dividend and outstanding growth. 10 stocks we like better than Pfizer › The healthcare sector has long been a favorite for income investors -- and for good reason. Many healthcare stocks offer attractive dividend yields. Some stocks stand out more than others, though. Here are the three healthcare stocks paying the highest dividends in 2025. 1. SIGA Technologies SIGA Technologies (NASDAQ: SIGA) focuses primarily on developing drugs for treating orthopoxviruses. Its flagship product is TPOXX, an antiviral medication that's approved in the U.S. and Canada for treating smallpox and in Europe, Japan, and the U.K. for treating smallpox, mpox, cowpox, and vaccinia complications. The company's dividend yield is a lofty 9.29%. However, there's something investors should know about SIGA's dividend. The drugmaker doesn't pay a regular dividend but, instead, has declared special cash dividends for four consecutive years. Special cash dividends usually aren't viewed as favorably by income investors as established programs that pay dividends on a monthly or quarterly basis. The risk that a company will decide against paying a special cash dividend in the future is probably higher than the risk that a company will suspend a regular dividend. SIGA's ability to pay dividends in the future depends largely on how seriously governments perceive the threat posed by smallpox, mpox, and other orthopoxviruses. For now, the threat level is high. That probably bodes well for the company declaring a special cash dividend in 2026, but it's difficult to predict what will happen with SIGA's dividend beyond then. 2. Pfizer Pfizer (NYSE: PFE) is the most well-known of the high-paying healthcare dividend stocks on this list. The company was founded in 1849. Today, it's one of the biggest drugmakers on the planet, with a market cap of over $130 billion and a lineup that includes multiple blockbuster drugs. Income investors have a lot to like about Pfizer. Its forward dividend yield stands at 7.32%. The company has paid a dividend for 346 consecutive quarters and has increased its dividend for 16 consecutive years. Its management team remains committed to sustaining and growing the dividend. Pfizer faces some challenges that could limit how much it's able to increase the dividend over the next few years, though. By the end of 2028, the company will lose patent protection for kidney cancer drug Inlyta, autoimmune disease drug Xeljanz, blood thinner Eliquis, breast cancer drug Ibrance, prostate cancer drug Xtandi, rare-disease franchise Vyndaqel/Vyndamx, and Mektovi, which treats melanoma and non-small cell lung cancer. While this patent cliff admittedly looks daunting, Pfizer's dividend shouldn't be in danger. The drugmaker has several rising stars, including migraine therapy Nurtec ODT and cancer drugs Padcev, Lorbrena, and Elrexfio. Pfizer's pipeline is also loaded with promising candidates, including 30 late-stage programs. 3. Spok Holdings Spok Holdings (NASDAQ: SPOK) specializes in healthcare communication and collaboration solutions. The company's flagship product, Spok Care Connect, is a unified communication platform that provides closed-loop communication, secure messaging, and collaboration capabilities to clinical teams. While Spok mainly focuses on hospitals, it also sells products to large government agencies, public-safety institutions, academic institutions, and other commercial customers. There's good news and bad news with Spok's dividend. First, the bad news: Don't expect dividend increases. Spok hasn't increased its dividend since 2022. The good news, though, is that the dividend is attractive, with a forward yield of 6.75%. Want more good news? Spok's business is booming. The company's earnings jumped 33% year over year in the second quarter of 2025. Its software operations bookings were 34% higher than the prior-year period. Unsurprisingly, Spok's stock has also performed well and is handily beating the market so far this year. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. 3 Healthcare Stocks Paying the Highest Dividends of 2025 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
34 minutes ago
- Bloomberg
How to Stay Safe as Smoky Air Blankets US
Hi! It's Madison in New York. If you've found it harder to breathe recently, you're not alone. But first... A couple months ago, I noticed that I was coughing a lot on my weekly runs. I've been running for years and I'm currently training for my third marathon, so it wasn't the result of simply being out-of-shape. Before long, I realized my cough was much worse on days when the air quality in New York was particularly bad. Recently, that's felt like more and more often.
